Cognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity: Maintenance Treatment
Cognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Connecticut
-
New Haven, Connecticut, United States, 06510
- Yale Department of Psychiatry
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- 18 to 64 years old
- Meets DSM-5 criteria for binge-eating disorder
- BMI 27-30 with a controlled obesity-related co-morbidity; or BMI ≥ 30 and <50
- Medically cleared as determined by EKG and medical record review
- Available for the duration of the treatment and follow-up (18 months)
- Read, comprehend, and write English at a sufficient level to complete study-related materials
- Able to travel to study location (New Haven, CT) for weekly visits
Exclusion Criteria:
- Previous history of problems with LDX or other stimulants
- Current psychostimulant use or use of any medication for ADHD
- Current use of study medications: LDX (Vyvanse), Bupropion (Wellbutrin, Zyban), Naltrexone, or Contrave
- History of congenital heart disease, known structural cardiac abnormalities, cardiomyopathy, serious heart arrhythmia, coronary artery disease, cerebrovascular pathology including stroke, exertional chest pain, uncontrolled high blood pressure, and other serious heart problems.
- History of severe renal, hepatic, neurological, or chronic pulmonary disease or other serious, unstable medical disorder.
- Current uncontrolled hypertension
- Current uncontrolled type I or II diabetes mellitus
- Current uncontrolled thyroid illness
- Gallbladder disease
- Co-occurring severe mental illness requiring hospitalization or intensive treatment
- Endorses current active suicidal or homicidal ideation with intent or plan
- History or current alcohol or substance use disorder (smoking is not exclusionary)
- Predisposition to seizures
- History of anorexia nervosa or bulimia nervosa, or currently regularly self-inducing vomiting
- Currently taking MAOI, SSRI or strong inhibitors of CYP2D6
- History of allergy or sensitivity to the study medication or stimulant medications
- Current use of medications contraindicated with the study medications
- Currently breast feeding or pregnant, or not willing to use reliable form of contraception
- Currently taking opioid pain medications or drugs
- Currently using effective treatment (evidence-based therapeutic or psychopharmacologic) for eating and/or weight loss
- Currently participating in another clinical study in which the participant is or will be exposed to an investigational or a non-investigational drug or device
- Medical status judged by study physician as contraindication
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo
|
Participants randomly assigned to this arm will receive 12 weeks of an inactive placebo.
|
|
Active Comparator: LDX
|
Participants randomly assigned to this arm will receive 12 weeks of LDX medication.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Binge-Eating Relapse
Time Frame: 12 weeks
|
Relapse will be scored as a yes/no (categorical variable); this categorical variable will be based on frequency of binge-eating episodes assessed using the Eating Disorder Examination interview; Relapse category will be defined as ≥4 binge-eating episodes per month.
|
12 weeks
|
|
Binge-Eating Relapse
Time Frame: 6-month follow-up
|
Relapse will be scored as a yes/no (categorical variable); this categorical variable will be based on frequency of binge-eating episodes assessed using the Eating Disorder Examination interview; Relapse category will be defined as ≥4 binge-eating episodes per month.
|
6-month follow-up
|
|
Binge-Eating Relapse
Time Frame: 12 month follow-up
|
Relapse will be scored as a yes/no (categorical variable); this categorical variable will be based on frequency of binge-eating episodes assessed using the Eating Disorder Examination interview; Relapse category will be defined as ≥4 binge-eating episodes per month.
|
12 month follow-up
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percent Change in Weight
Time Frame: From post-treatment to the 6-month follow-up
|
Negative values indicate weight loss and positive values indicate weight gain.
|
From post-treatment to the 6-month follow-up
|
|
Percent Change in Weight
Time Frame: From post-treatment to the 12-month follow-up
|
Negative values indicate weight loss and positive values indicate weight gain.
|
From post-treatment to the 12-month follow-up
|
|
Change in Eating-Disorder Psychopathology (Continuous)
Time Frame: From post-treatment to the 6-month follow-up
|
Eating-disorder psychopathology is a continuous variable as assessed by the global score of the Eating Disorder Examination/Eating Disorder Examination-Questionnaire. Scores range from 0-6 (0=no eating-disorder psychopathology; 6=severe eating-disorder psychopathology).
|
From post-treatment to the 6-month follow-up
|
|
Change in Eating-Disorder Psychopathology (Continuous)
Time Frame: From post-treatment to the 12-month follow-up
|
Eating-disorder psychopathology is a continuous variable as assessed by the global score of the Eating Disorder Examination/Eating Disorder Examination-Questionnaire. Scores range from 0-6 (0=no eating-disorder psychopathology; 6=severe eating-disorder psychopathology).
|
From post-treatment to the 12-month follow-up
|
|
Change in Depressive Symptoms
Time Frame: From post-treatment to the 6-month follow-up
|
Depressive symptoms is a continuous variable of depressive symptomatology as assessed by the self-report measure, the Beck Depression Inventory - Second Edition.
Scores range from 0-63 (0=no depressive symptoms, 63=greater depressive symptoms).
|
From post-treatment to the 6-month follow-up
|
|
Change in Depressive Symptoms
Time Frame: From post-treatment to the 12-month follow-up
|
Depressive symptoms is a continuous variable of depressive symptomatology as assessed by the self-report measure, the Beck Depression Inventory - Second Edition.
Scores range from 0-63 (0=no depressive symptoms, 63=greater depressive symptoms).
|
From post-treatment to the 12-month follow-up
|
|
Change in Binge-Eating Frequency
Time Frame: From baseline interview at study enrollment to 3 months after the 12-week treatment
|
Binge-eating frequency is a continuous variable of binge-eating episodes assessed using the Eating Disorder Examination interview; Binge-eating frequency will be based on the past 28 days and defined as binge-eating episodes per month.
|
From baseline interview at study enrollment to 3 months after the 12-week treatment
|
|
Change in Binge-Eating Frequency
Time Frame: From post-treatment to the 6-month follow-up
|
Binge-eating frequency is a continuous variable of binge-eating episodes assessed using the Eating Disorder Examination interview; Binge-eating frequency will be based on the past 28 days and defined as binge-eating episodes per month.
|
From post-treatment to the 6-month follow-up
|
|
Change in Binge-Eating Frequency
Time Frame: From post-treatment to the 12-month follow-up
|
Binge-eating frequency is a continuous variable of binge-eating episodes assessed using the Eating Disorder Examination interview; Binge-eating frequency will be based on the past 28 days and defined as binge-eating episodes per month.
|
From post-treatment to the 12-month follow-up
|
|
Change in Eating-Disorder Psychopathology (Continuous)
Time Frame: From baseline interview at study enrollment to 3 months after the 12-week treatment
|
Eating-disorder psychopathology is a continuous variable as assessed by the global score of the Eating Disorder Examination/Eating Disorder Examination-Questionnaire. Scores range from 0-6 (0=no eating-disorder psychopathology; 6=severe eating-disorder psychopathology).
|
From baseline interview at study enrollment to 3 months after the 12-week treatment
|
|
Change in Depressive Symptoms
Time Frame: From baseline interview at study enrollment to 3 months after the 12-week treatment
|
Depressive symptoms is a continuous variable of depressive symptomatology as assessed by the self-report measure, the Beck Depression Inventory - Second Edition.
Scores range from 0-63 (0=no depressive symptoms, 63=greater depressive symptoms).
|
From baseline interview at study enrollment to 3 months after the 12-week treatment
|
|
Percent Change in Weight
Time Frame: From baseline interview at study enrollment to 3 months after the 12-week treatment
|
Negative values indicate weight loss and positive values indicate weight gain.
|
From baseline interview at study enrollment to 3 months after the 12-week treatment
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Carlos M Grilo, Ph.D., Yale University
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Nutrition Disorders
- Overnutrition
- Body Weight
- Overweight
- Feeding and Eating Disorders
- Pathological Conditions, Signs and Symptoms
- Nutritional and Metabolic Diseases
- Signs and Symptoms
- Obesity
- Binge-Eating Disorder
- Organic Chemicals
- Amines
- Phenethylamines
- Ethylamines
- Amphetamines
- Dextroamphetamine
- Amphetamine
- Lisdexamfetamine Dimesylate
Other Study ID Numbers
Other Study ID Numbers
- 2000022480
- 1R01DK114075-01A1 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.